LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

Search

Aclaris Therapeutics Inc

Abrir

4.43 3.02

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.3

Máximo

4.53

Indicadores-chave

By Trading Economics

Rendimento

-29K

-20M

Vendas

701K

2M

EPS

-0.15

Margem de lucro

-993.186

Funcionários

69

EBITDA

-2.5M

-22M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+146.99% upside

Dividendos

By Acuity

Próximos Ganhos

5 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-24M

609M

Abertura anterior

1.41

Fecho anterior

4.43

Aclaris Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Sobre Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
help-icon Live chat